James E Bradner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3697203/publications.pdf

Version: 2024-02-01

211 papers	40,251 citations	3531 90 h-index	2828 191 g-index
219 all docs	219 docs citations	219 times ranked	43398 citing authors

#	Article	IF	Citations
1	Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	22
2	A novel Î²-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer. Science Advances, 2022, 8, eabm3108.	10.3	10
3	An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. Cell Chemical Biology, 2021, 28, 802-812.e6.	5.2	25
4	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Science Advances, 2021, 7, .	10.3	38
5	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Reports, 2021, 34, 108532.	6.4	54
6	Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances, 2021, 7, .	10.3	26
7	The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia, 2021, 23, 624-633.	5.3	8
8	Selective targeting of MYC mRNA by stabilized antisense oligonucleotides. Oncogene, 2021, 40, 6527-6539.	5.9	5
9	Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4 ⁺ T cells ex vivo. Science Advances, 2020, 6, eaba1941.	10.3	16
10	Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nature Communications, 2020, 11, 4687.	12.8	129
11	Evolutionary conserved NSL complex/BRD4 axis controls transcription activation via histone acetylation. Nature Communications, 2020, 11, 2243.	12.8	21
12	Selective Mediator dependence of cell-type-specifying transcription. Nature Genetics, 2020, 52, 719-727.	21.4	84
13	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Molecular Cell, 2020, 78, 1096-1113.e8.	9.7	114
14	BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. JCI Insight, 2020, 5, .	5.0	23
15	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. Journal of Clinical Investigation, 2020, 130, 5875-5892.	8.2	40
16	PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma. Nature Communications, 2019, 10, 3739.	12.8	49
17	Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465). Experimental Hematology, 2019, 75, 53-63.e11.	0.4	5
18	Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold. ACS Medicinal Chemistry Letters, 2019, 10, 1443-1449.	2.8	11

#	Article	IF	Citations
19	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nature Communications, 2019, 10, 4358.	12.8	109
20	Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nature Medicine, 2019, 25, 292-300.	30.7	120
21	The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. EBioMedicine, 2019, 44, 419-430.	6.1	76
22	MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nature Genetics, 2019, 51, 990-998.	21.4	61
23	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications, 2019, 10, 2400.	12.8	37
24	Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Research, 2019, 79, 994-1009.	0.9	17
25	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood, 2019, 133, 94-99.	1.4	21
26	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene, 2018, 37, 2850-2862.	5.9	71
27	Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nature Chemical Biology, 2018, 14, 405-412.	8.0	176
28	BET bromodomain proteins regulate enhancer function during adipogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2144-2149.	7.1	65
29	Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nature Genetics, 2018, 50, 515-523.	21.4	163
30	Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nature Communications, 2018, 9, 53.	12.8	175
31	Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders. ACS Chemical Biology, 2018, 13, 553-560.	3.4	128
32	Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nature Chemical Biology, 2018, 14, 163-170.	8.0	376
33	The dTAG system for immediate and target-specific protein degradation. Nature Chemical Biology, 2018, 14, 431-441.	8.0	629
34	Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood, 2018, 131, 771-781.	1.4	42
35	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. Cell, 2018, 172, 90-105.e23.	28.9	794
36	Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell, 2018, 33, 29-43.e7.	16.8	186

#	Article	IF	Citations
37	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chemical Biology, 2018, 25, 88-99.e6.	5.2	313
38	JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma. Molecular Cancer Therapeutics, 2018, 17, 107-118.	4.1	27
39	Leukemia-specific delivery of mutant NOTCH1 targeted therapy. Journal of Experimental Medicine, 2018, 215, 197-216.	8.5	30
40	Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell, 2018, 34, 982-995.e7.	16.8	101
41	Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Reports, 2018, 25, 3693-3705.e6.	6.4	23
42	A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. Nature Cell Biology, 2018, 20, 1410-1420.	10.3	265
43	NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model. Cancer Research, 2018, 78, 3709-3717.	0.9	38
44	Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5086-E5095.	7.1	87
45	Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chemical Biology, 2018, 13, 2438-2448.	3.4	44
46	Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 7785-7795.	6.4	46
47	Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5746-E5755.	7.1	20
48	Plasticity in binding confers selectivity in ligand-induced protein degradation. Nature Chemical Biology, 2018, 14, 706-714.	8.0	391
49	Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. ELife, 2018, 7, .	6.0	125
50	A chemical probe toolbox for dissecting the cancer epigenome. Nature Reviews Cancer, 2017, 17, 160-183.	28.4	76
51	ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature, 2017, 543, 265-269.	27.8	203
52	Transcription control by the ENL YEATS domain in acute leukaemia. Nature, 2017, 543, 270-274.	27.8	248
53	Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors. Israel Journal of Chemistry, 2017, 57, 319-330.	2.3	3
54	Transcriptional Addiction in Cancer. Cell, 2017, 168, 629-643.	28.9	843

#	Article	IF	Citations
55	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017, 18, 2162-2174.	6.4	244
56	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2017, 7, 852-867.	9.4	132
57	Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. Angewandte Chemie - International Edition, 2017, 56, 5738-5743.	13.8	207
58	Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. Angewandte Chemie, 2017, 129, 5832-5837.	2.0	14
59	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine, 2017, 9, .	12.4	53
60	BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Science Translational Medicine, 2017, 9, .	12.4	203
61	BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. Journal of Medicinal Chemistry, 2017, 60, 4805-4817.	6.4	39
62	Gene expression profiling of patientâ€derived pancreatic cancer xenografts predicts sensitivity to the <scp>BET</scp> bromodomain inhibitor <scp>JQ</scp> 1: implications for individualized medicine efforts. EMBO Molecular Medicine, 2017, 9, 482-497.	6.9	66
63	Pojamide: An HDAC3-Selective Ferrocene Analogue with Remarkably Enhanced Redox-Triggered Ferrocenium Activity in Cells. Organometallics, 2017, 36, 3276-3283.	2.3	28
64	HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Science Translational Medicine, 2017, 9, .	12.4	36
65	Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nature Communications, 2017, 8, 14400.	12.8	93
66	Epigenetic Reprogramming of Lineage-Committed Human Mammary Epithelial Cells Requires DNMT3A and Loss of DOT1L. Stem Cell Reports, 2017, 9, 943-955.	4.8	16
67	Prostate cancerâ€“associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine, 2017, 23, 1063-1071.	30.7	240
68	YY1 Is a Structural Regulator of Enhancer-Promoter Loops. Cell, 2017, 171, 1573-1588.e28.	28.9	749
69	Synthetic transcription elongation factors license transcription across repressive chromatin. Science, 2017, 358, 1617-1622.	12.6	110
70	BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Molecular Cell, 2017, 67, 5-18.e19.	9.7	347
71	Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. Bone, 2017, 94, 10-21.	2.9	51
72	A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. Frontiers in Microbiology, 2017, 8, 1035.	3.5	45

#	Article	IF	Citations
73	MELK is not necessary for the proliferation of basal-like breast cancer cells. ELife, 2017, 6, .	6.0	86
74	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. Journal of Clinical Investigation, 2017, 128, 446-462.	8.2	117
75	Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. PLoS Pathogens, 2017, 13, e1006668.	4.7	84
76	Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Oncotarget, 2016, 7, 24125-24140.	1.8	42
77	Ligand-Promoted Meta-Câ€“H Arylation of Anilines, Phenols, and Heterocycles. Journal of the American Chemical Society, 2016, 138, 9269-9276.	13.7	216
78	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nature Medicine, 2016, 22, 632-640.	30.7	176
79	High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. Cell Reports, 2016, 16, 2003-2016.	6.4	69
80	Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA. Cell Reports, 2016, 16, 1366-1378.	6.4	70
81	Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. Journal of Biological Chemistry, 2016, 291, 23756-23768.	3.4	48
82	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer, 2016, 122, 3632-3640.	4.1	145
83	BET and BRAF inhibitors act synergistically against BRAFâ€•mutant melanoma. Cancer Medicine, 2016, 5, 1183-1193.	2.8	41
84	Development of a Potent and Selective HDAC8 Inhibitor. ACS Medicinal Chemistry Letters, 2016, 7, 929-932.	2.8	59
85	Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discovery, 2016, 6, 1166-1181.	9.4	171
86	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Reports, 2016, 16, 2829-2837.	6.4	331
87	Chronic Myelogenous Leukemiaâ€“ Initiating Cells Require Polycomb Group Protein EZH2. Cancer Discovery, 2016, 6, 1237-1247.	9.4	72
88	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discovery, 2016, 6, 986-1005.	9.4	79
89	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics, 2016, 15, 2030-2041.	4.1	57
90	Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET-BRET. ChemMedChem, 2016, 11, 2575-2581.	3.2	17

#	Article	IF	Citations
91	Relative Binding Free Energy Calculations Applied to Protein Homology Models. Journal of Chemical Information and Modeling, 2016, 56, 2388-2400.	5.4	60
92	Design and characterization of bivalent BET inhibitors. Nature Chemical Biology, 2016, 12, 1089-1096.	8.0	115
93	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Research, 2016, 76, 6320-6330.	0.9	115
94	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13162-13167.	7.1	112
95	Eradication of Acute Myeloid Leukemia with FLT3 Ligandâ€“Targeted miR-150 Nanoparticles. Cancer Research, 2016, 76, 4470-4480.	0.9	48
96	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Reports, 2016, 15, 2692-2704.	6.4	92
97	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discovery, 2016, 6, 1006-1021.	9.4	108
98	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature, 2016, 530, 57-62.	27.8	318
99	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell, 2016, 164, 293-309.	28.9	399
100	MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science, 2016, 351, 1214-1218.	12.6	396
101	Models of human core transcriptional regulatory circuitries. Genome Research, 2016, 26, 385-396.	5.5	223
102	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	21.4	214
103	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature, 2016, 529, 413-417.	27.8	490
104	The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clinical Cancer Research, 2016, 22, 2534-2544.	7.0	100
105	Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. Oncotarget, 2016, 7, 72395-72414.	1.8	30
106	A Beadâ€Based Proximity Assay for BRD4 Ligand Discovery. Current Protocols in Chemical Biology, 2015, 7, 263-278.	1.7	21
107	Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood, 2015, 126, 1565-1574.	1.4	92
108	The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. Journal of Cellular Physiology, 2015, 230, 2683-2694.	4.1	58

#	Article	IF	Citations
109	Phthalimide conjugation as a strategy for in vivo target protein degradation. Science, 2015, 348, 1376-1381.	12.6	1,244
110	Tag and Capture Flow Hydrogen Exchange Mass Spectrometry with a Fluorous-Immobilized Probe. Analytical Chemistry, 2015, 87, 6349-6356.	6.5	1
111	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 232-237.	7.1	136
112	Structure-Guided DOT1L Probe Optimization by Label-Free Ligand Displacement. ACS Chemical Biology, 2015, 10, 667-674.	3.4	20
113	MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica, 2015, 100, e190-e193.	3.5	45
114	Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. Human Molecular Genetics, 2015, 24, 3982-3993.	2.9	51
115	An essential passenger with p53. Nature, 2015, 520, 626-627.	27.8	19
116	Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers. Molecular Cell, 2015, 58, 362-370.	9.7	382
117	Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nature Biotechnology, 2015, 33, 415-423.	17.5	237
118	Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood, 2015, 125, 2530-2543.	1.4	125
119	RNA Exosome-Regulated Long Non-Coding RNA Transcription Controls Super-Enhancer Activity. Cell, 2015, 161, 774-789.	28.9	370
120	DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nature Medicine, 2015, 21, 335-343.	30.7	200
121	Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole. Bioorganic and Medicinal Chemistry, 2015, 23, 5061-5074.	3.0	32
122	Chromatin proteomic profiling reveals novel proteins associated with histone-marked genomic regions. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3841-3846.	7.1	123
123	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	30.7	349
124	Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discovery, 2015, 5, 1210-1223.	9.4	575
125	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. Journal of Experimental Medicine, 2015, 212, 1819-1832.	8.5	137
126	Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Research, 2015, 43, 5880-5897.	14.5	136

#	Article	IF	Citations
127	Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. Cell Reports, 2015, 12, 1300-1313.	6.4	37
128	Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. Nucleic Acids Research, 2015, 43, 7790-7804.	14.5	33
129	Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010â€“2014). Pharmaceutical Patent Analyst, 2015, 4, 261-284.	1.1	36
130	Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2015, 21, 113-122.	7.0	119
131	High Throughput Screening Identifies Potential Inhibitors of WHSC1/MMSET, a Histone Methyltransferase Oncoprotein in Multiple Myeloma and Acute Lymphocytic Leukemia. Blood, 2015, 126, 3251-3251.	1.4	1
132	Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides. Blood, 2015, 126, 3784-3784.	1.4	2
133	Enhancer Landscapes Reveal Transcription Factor Network Dependencies in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 436-436.	1.4	3
134	JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1. Blood, 2015, 126, 822-822.	1.4	3
135	Structural Dynamics of the NSD Family Histone Methyltransferases. FASEB Journal, 2015, 29, 717.13.	0.5	0
136	Abstract A41: Shaping Myc-dependent transcriptional amplification. , 2015, , .		0
137	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. Journal of Cell Biology, 2015, 211, 2111OIA226.	5.2	0
138	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. Blood, 2015, 126, 435-435.	1.4	1
139	Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma. Blood, 2015, 126, 589-589.	1.4	2
140	Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma. Blood, 2015, 126, 838-838.	1.4	1
141	Therapeutic Strategies to Inhibit MYC. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a014266-a014266.	6.2	180
142	Convergent Transcription at Intragenic Super-Enhancers Targets AID-Initiated Genomic Instability. Cell, 2014, 159, 1538-1548.	28.9	221
143	Identification of ATRâ€“Chk1 Pathway Inhibitors That Selectively Target p53-Deficient Cells without Directly Suppressing ATR Catalytic Activity. Cancer Research, 2014, 74, 7534-7545.	0.9	25
144	AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes. Cancer Cell, 2014, 26, 896-908.	16.8	153

#	Article	IF	Citations
145	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2014, 26, 909-922.	16.8	376
146	From transcriptional regulation to drugging the cancer epigenome. Genome Medicine, 2014, 6, 123.	8.2	1
147	Activation of SOX2 Expression by BRD4-NUT Oncogenic Fusion Drives Neoplastic Transformation in NUT Midline Carcinoma. Cancer Research, 2014, 74, 3332-3343.	0.9	53
148	Quantitative ChIP-Seq Normalization Reveals Global Modulation of the Epigenome. Cell Reports, 2014, 9, 1163-1170.	6.4	442
149	The use of small molecules in somatic-cell reprogramming. Trends in Cell Biology, 2014, 24, 179-187.	7.9	60
150	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature Genetics, 2014, 46, 364-370.	21.4	333
151	Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature Genetics, 2014, 46, 618-623.	21.4	117
152	MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 652-665.	16.8	274
153	Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nature Communications, 2014, 5, 3511.	12.8	121
154	Genome-wide localization of small molecules. Nature Biotechnology, 2014, 32, 92-96.	17.5	165
155	BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma. Clinical Cancer Research, 2014, 20, 912-925.	7.0	296
156	The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science, 2014, 343, 305-309.	12.6	1,196
157	Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 9019-9027.	6.4	80
158	NF-Î°B Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis. Molecular Cell, 2014, 56, 219-231.	9.7	507
159	PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature, 2014, 514, 247-251.	27.8	386
160	7,9-Diaryl-1,6,8-trioxaspiro[4.5]dec-3-en-2-ones: Readily accessible and highly potent anticancer compounds. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4035-4038.	2.2	3
161	BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD. Molecular Cancer Therapeutics, 2014, 13, 2315-2327.	4.1	123
162	Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia. Cancer Research, 2014, 74, 7048-7059.	0.9	46

#	Article	IF	Citations
163	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Medicine, 2014, 20, 732-740.	30.7	255
164	A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia. Cell, 2014, 157, 369-381.	28.9	571
165	An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Research, 2014, 24, 809-819.	12.0	155
166	Notch inhibition allows oncogene-independent generation of iPS cells. Nature Chemical Biology, 2014, 10, 632-639.	8.0	64
167	MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene, 2014, 33, 1736-1742.	5.9	155
168	SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells. Blood, 2014, 124, 1566-1566.	1.4	3
169	Ongoing Spontaneous DNA Damage and the Role of Aberrant Epigenome in Multiple Myeloma. Blood, 2014, 124, 3398-3398.	1.4	2
170	Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells. PLoS ONE, 2014, 9, e87003.	2.5	51
171	Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents. Blood, 2014, 124, 420-420.	1.4	0
172	Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform. Blood, 2014, 124, 4811-4811.	1.4	0
173	Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells. Blood, 2014, 124, 918-918.	1.4	1
174	Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells. Blood, 2014, 124, 3534-3534.	1.4	0
175	BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. Journal of Molecular and Cellular Cardiology, 2013, 63, 175-179.	1.9	154
176	Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. Cancer Cell, 2013, 24, 777-790.	16.8	635
177	BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure. Cell, 2013, 154, 569-582.	28.9	346
178	Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers. Cell, 2013, 153, 320-334.	28.9	2,366
179	The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature, 2013, 498, 246-250.	27.8	278
180	PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains. Cancer Research, 2013, 73, 3336-3346.	0.9	218

#	Article	IF	Citations
181	BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle, 2013, 12, 452-462.	2.6	209
182	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery, 2013, 3, 308-323.	9.4	549
183	Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells. Blood, 2013, 122, 2842-2842.	1.4	1
184	Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL-Rearranged Leukemia. Blood, 2013, 122, 598-598.	1.4	4
185	BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood, 2012, 120, 2843-2852.	1.4	329
186	Small-Molecule Inhibition of BRDT for Male Contraception. Cell, 2012, 150, 673-684.	28.9	353
187	Transcriptional Amplification in Tumor Cells with Elevated c-Myc. Cell, 2012, 151, 56-67.	28.9	1,262
188	Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends in Immunology, 2012, 33, 563-570.	6.8	52
189	Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor. Blood, 2012, 120, 3558-3558.	1.4	2
190	Silencing c-Myc Using Myc Inhibitor JQ1 and EZH2 Inhibitor DZNep Blocks Converging Survival Signals in Aggressive B-Cell Lymphomas. Blood, 2012, 120, 4618-4618.	1.4	0
191	The Interaction Between DOT1L and AF10 Is Required for H3K79 Dimethylation and MLL-AF9 Leukemia. Blood, 2012, 120, 401-401.	1.4	0
192	Targeting Bromodomains in Myeloma. Blood, 2012, 120, SCI-6-SCI-6.	1.4	0
193	Targeting STAT5 in Leukemia Through Inhibition of Bromodomain Proteins. Blood, 2012, 120, 399-399.	1.4	1
194	Induction of Human Fetal Hemoglobin Expression by Selective Inhibitors of Histone Deacetylase 1 and 2 (HDAC1/2). Blood, 2012, 120, 3259-3259.	1.4	3
195	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature, 2011, 478, 524-528.	27.8	1,656
196	BET Bromodomain Inhibition asÂa Therapeutic Strategy to Target c-Myc. Cell, 2011, 146, 904-917.	28.9	2,432
197	Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma. Blood, 2011, 118, 1869-1869.	1.4	3
198	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	1.4	0

#	Article	IF	Citations
199	Induction of Fetal Hemoglobin by Inactivation of HDAC1 or HDAC2 without Altering Cellular Proliferation. Blood, 2011, 118, 354-354.	1.4	0
200	Selective inhibition of BET bromodomains. Nature, 2010, 468, 1067-1073.	27.8	3,456
201	Chemical phylogenetics of histone deacetylases. Nature Chemical Biology, 2010, 6, 238-243.	8.0	646
202	Treatment with Histone Deacetylase 6-Specific Inhibitor WT-161 Disrupts hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal ER Stress Induced by Proteasome Inhibitor Carfilzomib. Blood, 2010, 116, 2856-2856.	1.4	5
203	Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM). Blood, 2010, 116, 2997-2997.	1.4	2
204	Tubacin Kills Epstein-Barr Virus (EBV)-Burkitt Lymphoma Cells by Inducing Reactive Oxygen Species and EBV Lymphoblastoid Cells by Inducing Apoptosis. Journal of Biological Chemistry, 2009, 284, 17102-17109.	3.4	34
205	A pulse at the heart of targeted therapy. Nature Chemical Biology, 2009, 5, 144-145.	8.0	1
206	In Vivo Pharmacodynamic Imaging of Proteasome Inhibition. Molecular Imaging, 2009, 8, 7290.2009.00007.	1.4	40
207	Discovery and Characterization of Macrocyclic Thiopeptide Proteasome Inhibitors for Hematologic Malignancies. Blood, 2008, 112, 3669-3669.	1.4	0
208	A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.. Blood, 2007, 110, 800-800.	1.4	2
209	Targeting Histone Deacetylase 6 and the Aggresome Pathway in Acute Lymphoblastic Leukemia Cells.. Blood, 2007, 110, 1602-1602.	1.4	0
210	Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.. Blood, 2006, 108, 3426-3426.	1.4	0
211	Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules.. Blood, 2005, 106, 2471-2471.	1.4	0